Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

O’Toole, Aoibhlinn; Lucci, Matthew; Korzenik, Joshua R.

doi:10.1007/s10620-015-4007-z

Cited by 57 publications

(45 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients treated with anti-TNF therapy were also reported for increased risk for demyelinating disorders, like multiple sclerosis, optic neuritis, and acute transverse myelitis [44, 45]; paradoxical psoriasis consisting of severe skin lesions was observed in IBD patients treated with anti-TNF agents [46]. In addition, unlike anti-TNF antibodies, etanercept, which is not effective for the treatment of IBD, was correlated with the development of newly diagnosed ulcerative colitis and Crohn's disease in treated patients [47, 48]. …”

Section: Anti-inflammatory Cytokine Biologicsmentioning

confidence: 99%

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

Rider

Carmi

Bar‐Sela

2016

International Journal of Cell Biology

168

111

View full text Add to dashboard Cite

Proinflammatory cytokines are potent mediators of numerous biological processes and are tightly regulated in the body. Chronic uncontrolled levels of such cytokines can initiate and derive many pathologies, including incidences of autoimmunity and cancer. Therefore, therapies that regulate the activity of inflammatory cytokines, either by supplementation of anti-inflammatory recombinant cytokines or by neutralizing them by using blocking antibodies, have been extensively used over the past decades. Over the past few years, new innovative biological agents for blocking and regulating cytokine activities have emerged. Here, we review some of the most recent approaches of cytokine targeting, focusing on anti-TNF antibodies or recombinant TNF decoy receptor, recombinant IL-1 receptor antagonist (IL-1Ra) and anti-IL-1 antibodies, anti-IL-6 receptor antibodies, and TH17 targeting antibodies. We discuss their effects as biologic drugs, as evaluated in numerous clinical trials, and highlight their therapeutic potential as well as emphasize their inherent limitations and clinical risks. We suggest that while systemic blocking of proinflammatory cytokines using biological agents can ameliorate disease pathogenesis and progression, it may also abrogate the hosts defense against infections. Moreover, we outline the rational need to develop new therapies, which block inflammatory cytokines only at sites of inflammation, while enabling their function systemically.

show abstract

Section: Anti-inflammatory Cytokine Biologicsmentioning

confidence: 99%

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

Rider

Carmi

Bar‐Sela

2016

International Journal of Cell Biology

168

111

View full text Add to dashboard Cite

show abstract

“…Choice of therapy should take into consideration factors such as extra‐articular manifestations of SpA like uveitis, inflammatory bowel disease and skin psoriasis, and social factors including financial cost, convenience and insurance coverage. For instance, etanercept is associated with higher risk of anterior uveitis and inflammatory bowel disease and thus should be avoided in patients with these concurrent conditions . Similarly, there is no evidence to show that IL17i is effective in inflammatory bowel disease and other bDMARDs may be preferred in these patients .…”

Section: Resultsmentioning

confidence: 99%

“…To date, there is are still no head-to-head trials comparing different TNFi, or between TNFi and IL17i. Choice of therapy should take into 39,40 Similarly, there is no evidence to show that IL17i is effective in inflammatory bowel disease and other bDMARDs may be preferred in these patients. 41 Skin psoriasis is also another important extra-articular manifestation to consider.…”

Section: The Choice Of Bdmard Should Take Into Consideration Patienmentioning

confidence: 99%

Update on recommendations for eligibility of government subsidization of biologic disease‐modifying antirheumatic drugs for the treatment of axial spondyloarthritis in Singapore

et al. 2019

View full text Add to dashboard Cite

Aims The field of axial spondyloarthritis (axSpA) has undergone significant changes recently in particular with disease classification, assessment of disease activity and increased treatment options for biologics. In order to reflect these developments, we aimed to update the local consensus recommendations for subsidization of biologics. Methods A modified Delphi approach was used. Six published guidelines from major rheumatology societies and healthcare authorities on axSpA were reviewed. Findings were synthesized and used in formulating updated recommendation statements. Recommendations were rated by 10 practicing rheumatologists in Singapore. Consensus was reached if there was more than 70% agreement or disagreement. Results Ten statements achieved consensus. Patients may be considered for subsidization of biologic therapy if they fulfill the Assessment of Spondyloarthritis International Society or modified New York criteria, with persistently active disease (defined either by Ankylosing Spondylitis Disease Activity Score ≥ 2.1 or Bath Spondylitis Disease Activity Index ≥ 4), despite 4 weeks of full‐dose non‐steroidal anti‐inflammatory drugs and regular exercise. Either tumor necrosis factor inhibitors or interleukin 17 inhibitors may be used as first‐line therapy, and should be continued if adequate response is achieved at 6 months. Conclusion Recommendation statements were formulated through a formal consensus process by local experts with a view to assist relevant authorities in funding considerations and for use in clinical practice.

show abstract

“…Indeed, this is reflected in the preferential prescription of ADA,6 7 9 resulting in indication bias in observational studies. ADA is also an effective treatment for inflammatory bowel disease,13 whereas ETA is not 14…”

Section: Discussionmentioning

confidence: 99%

Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?

Hunter

2018

Arch Dis Child

View full text Add to dashboard Cite

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

Cited by 57 publications

References 15 publications

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

Update on recommendations for eligibility of government subsidization of biologic disease‐modifying antirheumatic drugs for the treatment of axial spondyloarthritis in Singapore

Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?

Contact Info

Product

Resources

About